Protalix BioTherapeutics (PLX) Gross Profit (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Gross Profit of $29.6 million for Q1 2026, up 1432.49% year-over-year from $1.9 million in Q1 2025, and up 557.85% quarter-over-quarter from $4.5 million in Q4 2025.
Protalix BioTherapeutics (PLX) Gross Profit (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $29.6 million for Q1 2026.
- In Q1 2026, Gross Profit rose 1432.49% year-over-year to $29.6 million; the TTM figure through Mar 2026 stood at $53.4 million (up 78.93% YoY), while the FY2025 annual figure was $25.8 million, down 11.45% from the prior year.
- Gross Profit for Q1 2026 stood at $29.6 million, up from $4.5 million in the prior quarter.
- The five-year high for Gross Profit was $29.6 million in Q1 2026, with the low at $1.1 million in Q1 2024.
- The 5-year median for Gross Profit is $6.5 million (2023), against an average of $9.1 million.
- The sharpest annual moves came in 2024 and 2026: Gross Profit tumbled 86.11% in 2024, then surged 1432.49% in 2026.
- Protalix BioTherapeutics' Gross Profit stood at $6.2 million in 2022, then sank by 73.79% to $1.6 million in 2023, then surged by 779.26% to $14.3 million in 2024, then sank by 68.58% to $4.5 million in 2025, then surged by 557.85% to $29.6 million in 2026.
- Business Quant data shows PLX's Gross Profit at $29.6 million in Q1 2026, $4.5 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.13 Mn |
| Jun 30, 2026 | 12.13 Mn |
| Mar 31, 2026 | 29.62 Mn |
| Mar 31, 2026 | 29.62 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 9.53 Mn |
| Sep 30, 2025 | 9.53 Mn |
| Jun 30, 2025 | 9.79 Mn |
| Jun 30, 2025 | 9.79 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 14.33 Mn |
| Dec 31, 2024 | 14.33 Mn |
| Sep 30, 2024 | 9.58 Mn |
| Sep 30, 2024 | 9.58 Mn |
| Jun 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 4.02 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.15 Mn |